📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-19 18:44
570 analysed today
570
Today
133,459
All-time analysed
40,112
Positive
6,281
Negative
79,251
Neutral
7,747
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
5 announcements match the current filters (relevance ≥ 5).
Sudarshan Pharma allots 48.12 lakh shares on conversion of $1.5M FCCBs
Sudarshan Pharma Industries has approved the allotment of 48,11,730 equity shares of face value Re 1 each following the conversion of Foreign Currency Convertible Bonds (FCCBs) worth USD 1.5 million (USD 15,00,000). The shares were allotted at an issue price of Rs 30.19 per share (including a premium of Rs 29.19 per share). This conversion expands the company's total issued equity share base by ~1.93% from 24,96,58,870 to 25,44,70,600 shares.
Confidence: HIGH
What changedSudarshan Pharma issued 48.12 lakh new equity shares upon conversion of USD 1.5M FCCBs, increasing the total share count to 25.45 crore shares.
Why it mattersThe FCCB conversion reduces foreign currency debt liabilities while causing minor equity dilution of ~1.93% on the pre-issue base.
Shares allotted: 48,11,730FCCB conversion value: USD 15,00,000Issue price per share: Rs.30.19Post-issue share count: 25,44,70,600Equity dilution (pre-issue base): ~1.93%
📅 Short termNeutral trading impact as the ~1.9% equity dilution is modest and expected from prior FCCB issuances.
📈 Long termLimited operational impact; slightly strengthens the balance sheet net worth by substituting debt with equity.
⚠ Risk flags
- Minor equity dilution of existing shareholders
Key Highlights
Allotted 48,11,730 equity shares of face value Re 1 upon conversion of FCCBs worth USD 15,00,000
Shares issued at Rs 30.19 per share (face value Re 1 + premium Rs 29.19 per share)
Total paid-up equity share capital increases from Rs 24.97 Cr to Rs 25.45 Cr
In-principle approval from BSE was received on 26th September 2025
👀 What to Watch
Track subsequent shareholding pattern updates to assess promoter stake dilution and monitor any remaining outstanding FCCBs that could cause future equity dilution.
Sudarshan Pharma details acquisition of 584 KL USFDA-approved API plant
Sudarshan Pharma has released technical details for its proposed acquisition of a 14-acre API manufacturing facility near Visakhapatnam. The plant has a total capacity of 584 KL across four manufacturing blocks and is equipped with USFDA (2024) and ANVISA (2025) approvals. This acquisition is part of a larger Rs 355 Cr strategic plan to transition from trading to high-margin manufacturing, targeting an EBITDA margin improvement from 4.9% to over 8.4%. The facility currently serves major clients including Cipla, Dr. Reddy's, and Laurus Labs.
Confidence: HIGH
What changedThe company has moved from a general intent to acquire assets to providing specific operational and regulatory details of a high-value USFDA-approved target plant.
Why it mattersThis represents a major structural shift from a trading-led business model to a manufacturing-led one, which is essential for achieving the company's 20% growth target and margin expansion goals.
Total Plant Capacity: 584 KLTotal Planned Acquisition Value: Rs 355 CrAcquisition Value vs TTM Revenue: ~48.5%Acquisition Value vs Market Cap: ~42.6%Employee Count: 200
📅 Short termThe market is likely to react positively to the high quality of the target asset (USFDA/ANVISA approvals) and the blue-chip client list.
📈 Long termIf successfully integrated, this acquisition could structurally re-rate the company by significantly increasing the share of high-margin API manufacturing in the revenue mix.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High Debt-to-Equity ratio (1.84) may increase further depending on acquisition funding
- Execution risk in transitioning from trading to complex API manufacturing
Key Highlights
Total manufacturing capacity of 584 KL across 4 multi-product blocks and a solvent recovery system
Facility holds major regulatory approvals including USFDA (2024), WHO Geneva (2024), and ANVISA (2025)
Site spans 14 acres and employs 200 personnel across operations, R&D, and quality control
Planned total acquisition outlay of Rs 355 Cr represents approximately 48.5% of TTM revenue
Established customer base featuring 19 domestic majors like Mylan and Glenmark, plus 11 export clients
👀 What to Watch
Watch for the final acquisition price and funding structure, as the company's current Debt-to-Equity ratio is already high at 1.84. Monitor the timeline for operational integration and its impact on quarterly OPM.
76% Acquisition of Vizag Pharma Co with Rs 154 Cr Revenue and US FDA Plant
Sudarshan Pharma Industries Ltd (SPIL) has signed an MoU to acquire a 76% stake (1.24 crore shares) in a Vizag-based pharmaceutical manufacturing company. The target entity reported FY26 revenue of Rs 154.37 Cr, which is approximately 21% of SPIL's TTM revenue, indicating a significant scale-up. The facility includes 4 manufacturing blocks with a 576.10 KL capacity and holds prestigious approvals including US FDA and WHO Geneva. The transaction involves cash and a transfer of 40 lakh shares from SPIL's promoters, with a target completion date of October 10, 2026.
Confidence: HIGH
What changedSPIL has moved from intent to a formal MoU for a major acquisition that adds significant manufacturing capacity and high-standard regulatory approvals.
Why it mattersThis acquisition facilitates backward integration and provides SPIL with the infrastructure to target regulated markets like the US and Europe, potentially improving its current 7.6% operating margins.
Target Revenue (FY26): Rs 154.37 CrTarget vs SPIL TTM Revenue: ~21.1%Manufacturing Capacity: 576.10 KLStake Acquired: 76%Completion Date: 10th October 2026
📅 Short termThe stock is likely to react positively to the scale of the acquisition and the quality of the target's manufacturing assets (US FDA).
📈 Long termThis is a structural shift for SPIL, moving it toward a manufacturing-led model which could lead to higher margins and better export opportunities over the next 2-3 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Final acquisition cost not yet disclosed
- Subject to successful due diligence
- Integration of a large manufacturing facility into existing operations
Key Highlights
Acquisition of 76% stake in a target company with a manufacturing capacity of 576.10 KL
Target company revenue of Rs 154.37 Cr in FY26, representing ~21% of SPIL's TTM revenue
Facility holds high-value accreditations including US FDA, WHO Geneva, and Anvisa
Deal structure includes cash consideration and 40 lakh shares offered by SPIL promoters
Expected completion of the acquisition process by October 10, 2026
👀 What to Watch
Investors should monitor the final valuation disclosure and the successful completion of due diligence by the October 10 deadline. The integration of a US FDA-approved plant is a key milestone for SPIL's transition from trading to manufacturing.
51% Stake Divestment: Sudarshan Pharma to Exit Ishwari Healthcare Subsidiary
Sudarshan Pharma Industries Ltd (SPIL) has approved the divestment of its 51% stake (2,09,100 equity shares) in its subsidiary, Ishwari Healthcare Private Limited. The subsidiary reported a total income of Rs 7.46 crore for FY26, which represents approximately 1.02% of SPIL's TTM revenue of Rs 732 crore. The transaction is expected to be completed by December 31, 2026, with the final sale price to be determined after a formal valuation. This move appears to be a minor portfolio rationalization as the company focuses on its larger manufacturing and export expansion goals.
Confidence: HIGH
What changedSudarshan Pharma is exiting its majority position in Ishwari Healthcare, transitioning it from a subsidiary to an unrelated entity.
Why it mattersThe divestment is financially small (~1% of revenue) but indicates a streamlining of operations. It allows management to focus on its core strategy of vertical integration and larger planned acquisitions of Rs 355 crore.
Stake being sold: 51.00%Subsidiary Revenue (FY26): Rs 7.46 CrSubsidiary Revenue vs TTM Revenue: ~1.02%Expected Completion Date: 31st December 2026Subsidiary Paid-up Capital: Rs 41 Lakhs
📅 Short termNeutral impact expected as the subsidiary's contribution to the consolidated top-line is minimal.
📈 Long termLimited structural significance; the exit from a small subsidiary is likely part of a broader strategy to focus on high-value oncology APIs and specialty chemicals.
⚠ Risk flags
- Buyer not yet identified
- Final valuation and consideration amount are currently unknown
Key Highlights
Divestment of 2,09,100 equity shares representing 51.00% of Ishwari Healthcare's paid-up capital
Ishwari Healthcare contributed Rs 7.46 crore in total income during FY26
Target completion date for the divestment is set for December 31, 2026
Ishwari Healthcare will cease to be a subsidiary of the company upon completion
Management has been delegated powers to find a buyer at a competitive price
👀 What to Watch
Monitor the final valuation and sale consideration to see if the proceeds are used for debt reduction, given the company's high Debt-to-Equity ratio of 1.84.
Q1 Net Profit Up 62% YoY to ₹6.04 Cr; USD 10M FCCB Allotted for Expansion
Sudarshan Pharma reported a strong year-on-year performance for Q1 FY27, with consolidated revenue rising 20% to ₹174.42 Cr. Standalone net profit grew 62% YoY to ₹6.04 Cr, although it saw a sequential decline from Q4 FY26. The company is aggressively pursuing its expansion strategy, having allotted USD 10 million in 8% FCCBs and incorporating a new subsidiary in the USA. Additionally, the company decided to shut down its Palghar manufacturing unit to rationalize costs and focus on more profitable operations.
Confidence: HIGH
What changedThe company has transitioned from a purely domestic focus to incorporating a US subsidiary and has successfully tapped international debt markets via FCCBs.
Why it mattersThe strong YoY growth and successful fundraise support the company's strategy to shift from trading to high-margin manufacturing and international expansion, though the high debt-to-equity ratio remains a key metric to watch.
Consolidated Revenue (Q1): ₹174.42 CrStandalone PAT (YoY Growth): 62%FCCB Allotment Value: USD 10,000,000FCCB vs Market Cap: ~10.3%Promoter Warrant Conversion Receipt: ₹11.46 Cr
📅 Short termThe market is likely to react positively to the strong YoY profit growth and the successful initial tranche of the FCCB fundraise.
📈 Long termThe structural shift toward manufacturing and global presence through the US subsidiary could re-rate the business if the planned ₹355 Cr acquisitions are accretive.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High Debt-to-Equity ratio (1.84)
- Heavy reliance on China (70-80%) for API intermediates
- Potential equity dilution from FCCB conversions
Key Highlights
Consolidated revenue increased 20% YoY to ₹174.42 Cr from ₹145.26 Cr.
Standalone PAT grew 62% YoY to ₹6.04 Cr, though down from ₹9.54 Cr in the previous quarter.
Allotted USD 10 million (~₹83 Cr) in 8% senior unsecured FCCBs due 2029 at a conversion price of ₹30.19.
Received ₹4.68 Cr out of a total ₹9.19 Cr legal award from a Dubai court litigation.
Discontinued manufacturing operations at the Palghar unit to minimize losses and rationalize fixed costs.
👀 What to Watch
Monitor the deployment of FCCB proceeds toward the planned ₹355 Cr acquisition pipeline and observe if the Palghar unit closure leads to improved EBITDA margins in the next two quarters.
